Lung Cancer Surgery Market Size, Share, Growth Analysis, By Device(Surgical instruments, monitoring & visualizing systems and endosurgical equipment), By End-User(Hospitals and Ambulatory Surgery Centers) - Industry Forecast 2024-2031

Lung Cancer Surgery Market size was valued at USD 5.43 billion in 2021 and is poised to grow from USD 5.65 billion in 2022 to USD 8.11 billion by 2030, at a CAGR of 4.1% during the forecast period (2023-2030).

The lung cancer surgery market features a competitive landscape with several key players operating in the industry. These companies are actively involved in research and development, strategic collaborations, mergers and acquisitions, and product innovations to gain a competitive edge. These companies face competition from both established players and emerging companies in the lung cancer surgery market. The competitive landscape is driven by factors such as technological advancements, product quality, clinical outcomes, pricing strategies, and geographical presence. Market players strive to gain market share by offering innovative and effective solutions for lung cancer surgery while maintaining high standards of patient safety and satisfaction. 'Medtronic (US)', 'Johnson & Johnson (US)', 'Intuitive Surgical (US)', 'Ethicon (US)', 'Olympus Corporation (Japan)', 'Karl Storz SE & Co. KG (Germany)', 'Teleflex Incorporated (US)', 'Medrobotics Corporation (US)', 'Siemens Healthineers AG (Germany)', 'Accuray Incorporated (US)', 'GE Healthcare (US)', 'Novartis AG (Switzerland)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Boston Scientific Corporation (US)', 'Cook Medical Incorporated (US)', 'AngioDynamics (US)', 'Merck & Co., Inc. (US)', 'Becton, Dickinson and Company (US)', 'Varian Medical Systems, Inc. (US)', 'Stryker Corporation (US)'

The greatest cause of death for both men and women worldwide is lung cancer. Because the tobacco epidemic started in several developing nations and among populations there, lung cancer incidence and mortality are rising globally. The impact of lung cancer on individuals and families is significant, and it is often viewed as a threat to health. A malignant tumor known as lung cancer is characterized by the unchecked proliferation of lung cell tissues.

Shift Increasing Research and Development: Extensive research and development activities are being conducted to explore new treatment modalities, refine surgical techniques, and develop novel technologies in the field of lung cancer surgery. Clinical trials are ongoing to evaluate the efficacy and safety of innovative approaches, including targeted therapies, immunotherapies, and minimally invasive procedures.

The dominating region in the Lung Cancer Surgery market is North America, which holds a significant market share. The region has a well-established healthcare infrastructure, advanced surgical facilities, and a high prevalence of lung cancer cases. Moreover, there is a strong emphasis on early detection, effective treatment options, and favorable reimbursement policies, contributing to the dominance of North America in the market. Leading players in the industry, technological advancements, and a robust research and development environment further strengthen the market position of North America.